Grapheal raises €1.9m to develop graphene-based biosensors
The Grapheal team. Image: Grapheal
The medtech start-up will use the funds to support the development of a digital Covid-19 test and wound-monitoring biosensors.
As the pandemic continues, many start-ups in the health space have seen an influx of investment. According to Pitchbook’s European Venture Report for 2020, investment in biotech and pharma start-ups jumped by more than 40pc year-on-year.
Now, a French medtech company specialising in graphene-based wearable sensors has secured €1.9m in equity and non-dilutive sources.
Founded in 2019, Grapheal develops wearable and disposable sensors that enable continuous monitoring and diagnosis. The company is a spin-out from the Neel Institute at the French National Centre for Scientific Research.
Laxman Pai, Opalesque Asia:
European VC deal value hitting a new annual record of €42.8 billion across 9,341 deals, representing a 14.8% YoY increase in value from the previous record set in 2019, said a study.
According to PitchBook s 2020 Annual European Venture Report, firms raised €19.6 billion for new venture funds in 2020, another new all-time high, it said. VC deal value remained aloft despite COVID-19 and set a new annual record, a noteworthy achievement considering macroeconomic damage delivered by the pandemic, it said.
The deluge of capital deposited into larger rounds did not relent in 2020. Pandemic-induced opportunities and existing VC companies within technology and healthcare have been well-positioned to grow. VC investment into the UK stayed robust despite Brexit, and capital from the US flowed freely into Europe in 2020.
/PRNewswire/ PitchBook, the premier data provider for the private and public equity markets, today released its 2020 Annual European Venture Report, which.